Contribution of serotonin to cardiac remodeling associated with hypertensive diastolic ventricular dysfunction in rats

Estelle Ayme-Dietrich (1) , Halim Marzak , Roland Lawson , Walid Mokni (2) , Olivia Wendling (3) , Roy Combe (4) , Julien Becker (5) , Lahcen El Fertak (3) , Marie-France Champy (3) , Rachel Matz (2) , Ramaroson Andriantsitohaina (6) , Stéphane Doly (7) , Katia Boutourlinsky (8) , Luc Maroteaux (9) , Laurent Monassier (10)

1 Service de génétique moléculaire, pharmacogénétique et hormonologie
2 LBP - Laboratoire de Biophotonique et Pharmacologie - UMR 7213
3 ICS - Institut Clinique de la Souris
4 ICS - Institut Clinique de la Souris
5 Inflammation et environnement dans l'asthme
6 BNVI - Biologie Neurovasculaire Intégrée
7 IC UM3 (UMR 8104 / U1016) - Institut Cochin
8 NPS - Neuroscience Paris Seine
9 Institut du Fer à Moulin
10 Régulation nerveuse de la fonction cardiovasculaire

Left-ventricular hypertrophy and interstitial fibrosis are the main pathophysiological factors of heart failure with preserved ejection fraction. Blockade of the serotonin 5-HT2B receptor (5-HT2BR) has been shown to reduce cardiac hypertrophy, oxidative stress, and extracellular cell matrix activation. In this study, we evaluated the effects of the 5-HT2BR blockade, on hemodynamic and cardiac remodeling, in spontaneously hypertensive rats (SHRs) that display a diastolic dysfunction with preserved ejection fraction.

Domaines: Pharmacologie; Neurobiologie; Cardiologie et système cardiovasculaire; Psychiatrie et santé mentale; Pneumologie et système respiratoire; Génétique animale; Biologie moléculaire

Estelle Ayme-Dietrich, Halim Marzak, Roland Lawson, Walid Mokni, Olivia Wendling, et al.. Contribution of serotonin to cardiac remodeling associated with hypertensive diastolic ventricular dysfunction in rats. Journal of Hypertension, 2015, 33 (11), pp.2310 - 2321. ⟨10.1097/HJH.0000000000000695⟩. ⟨hal-01593863⟩